Seattle, WA, United States of America

Leonard Eggleston

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Nestec S.a.. Active years: 2017.

USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Leonard Eggleston: Innovator in Crohn's Disease Diagnosis

Introduction

Leonard Eggleston is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of medical diagnostics, particularly concerning inflammatory bowel disease (IBD). His innovative work aims to improve the prognosis and management of Crohn's disease-related complications.

Latest Patents

Leonard Eggleston holds a patent for a "Method for determining the risk of Crohn's disease-related complications." This invention provides methods and systems that are useful in diagnosing IBD and predicting the progression of the disease. With this invention, healthcare professionals can better assess the risk of complications and the likelihood of patients requiring surgical intervention.

Career Highlights

Eggleston is currently employed at Nestec S.A., where he continues to develop innovative solutions in the medical field. His work focuses on enhancing diagnostic methods that can lead to better patient outcomes.

Collaborations

Leonard collaborates with talented professionals, including Fred Princen and Derren Barken, who contribute to his research and development efforts.

Conclusion

Leonard Eggleston's contributions to the diagnosis and management of Crohn's disease highlight the importance of innovation in healthcare. His patent reflects a commitment to improving patient care through advanced diagnostic methods.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…